

Marico

Well oiled for growth

We upgrade Marico to BUY from ADD with TP of Rs 650 (45x FY26 EPS, 10% premium to its 5 year Average PE) and move it to high conviction list within staples pack as worst is behind us wr.t muted volume growth, pricing correction, loss related to new business and transient currency headwinds. We expect Marico to see Revenue/ Ebitda / PAT Cagr of 6/13/13% respectively over FY23-26 as 1) Domestic business fires on all cylinders -(a) Parachute (35% of domestic sales) expected to see mid-single volume growth on back of market share gains and conversion from unbranded to branded, as we have always seen in inflationary copra environment. Moreover, we expect double digit revenue growth in FY25 on back of mid to single digit price hikes (b) Saffola edible oil (20% of domestic sales) expected to see volume led mid single digit value growth in FY25, courtesy pricing correction anniversarian (down 20% in FY24) (c) VAHO - easing competitive intensity in BOP segment along with uptick in mid to premium end segment shall drive much better outcomes. 2) Significant improvement in profitability of fast-growing foods and digital first business (20% of domestic sales) 3) Sustaining double digit constant currency revenue growth momentum in International business as worst related to currency headwinds is behind us. Key risks to our call - 1) Volatility in RM index, as copra still forms 35% of RM basket 2) Increased competitive intensity in VAHO segment.

- **Domestic business to fire on all cylinders**: Parachute (35% of domestic sales) expected to see mid-single volume growth (after seeing 1% volume growth in FY23) on back of market share gains and conversion from unbranded to branded, as we have always seen in inflationary copra environment. We have penciled in 11% revenue growth in FY25 on pack of 6% price hikes taken till date. Mgmt. intends to take more price hikes, if inflation in RM index sustains (b) Saffola edible oil (20% of domestic sales) expected to see volume led mid single digit value growth (declined 19% in FY24) in FY25, courtesy pricing correction anniversarian (down 20% in FY24) (c) VAHO – easing competitive intensity in BOP segment (shanti amla, Nihar naturals sarson kesh tel) along with uptick in mid to premium end segment shall drive much better profitability outcome. Incrementally, Marico has embarked upon project SETU, where it intends to increase direct reach from 1 mn outlets in FY24 to 1.5 mn outlets in FY27 and will involve an outlay of Rs 0.8-1 bn over a span of 3 years; with majority of the investments for the project coming from optimizing wholesale channel spends and savings from reducing supply chain costs. Notably, Project SETU shall help to drive market share gains across categories in urban and rural, as well as enhance assortment levels in urban stores, thereby enabling diversification & premiumization in the domestic business.
- Substantial improvement in margin profile of fast growing foods and digital first brands (20% of total sales): Foods business (10% of domestic sales) has seen c800bps gross margin improvement in FY24; courtesy benign RM index, increased share of in-house manufacturing, supply chain reconfiguration and economies of scale from soya chunks and honey business. Similarly, mgmt. is gunning for double digit EBITDA margin by FY27 for its digital first brand business (10% of domestic sales) on back of improving scale and premiumization. At an aggregate basis, mgmt. intends to increase contribution of fast growing business from 20% of domestic sales in FY24 to 25% of sales in FY27

BUY

CMP (as on 6	INR 530		
Target Price	INR 650		
NIFTY	22,443		
KEY CHANGES	OLD	NEW	
Rating	ADD	BUY	
Price Target	INR 650	INR 650	
EPS %	FY25E	FY26E	
EF3 %	1%	-1%	

KEY STOCK DATA

Bloomberg code	MRCO IN
No. of Shares (mn)	1,294
MCap (INR bn) / (\$ mn)	686/8,215
6m avg traded value (INR r	mn) 812
52 Week high / low	INR 595/486

STOCK PERFORMANCE (%)

Absolute (%) 1.8 (0.7)	7.4
Relative (%) (0.5) (14.5) (13	.6)

SHAREHOLDING PATTERN (%)

	Dec-23	Mar-24
Promoters	59.39	59.39
FIs & Local MFs	9.96	10.09
FPIs	25.69	25.54
Public & Others	4.96	4.98
Pledged Shares	0.00	0.00
Source · BSF		

Source : BSE

Pledged shares as % of total shares

Vishal Gutka

vishal.gutka@hdfcsec.com +91-22-6171-7324

Riddhi Shah


riddhi.shah@hdfcsec.com +91-22-6171-7359





• Improved confidence in revenue momentum of International business: Management is gunning for constant currency double digit revenue growth for FY25 as macro headwinds related to Bangladesh (40% of international business) behind us and strong revenue growth construct for MENA and South Africa business. Marico will continue to invest aggressively towards diversifying the portfolio, expanding the total addressable market and driving market share gains in each of the markets

Marico trades at 35x, almost at significant discount to its 3 year Average PE of 43x



4QFY24 Concall Takeaways

(1) Despite moderate uptick in rural growth, premiumization was leading over mass category. (2) Revival in PCNO category accompanied by uptick in 'loose to branded conversion' and ~6% price hike from Q1FY25 as copra prices are firming up. (3) Saffola edible oil volume/value grew mid-single digit/revenue decline, price correction to bottom out from Q2FY25 (4) VAHO remained weak on account of high base, competitive intensity and shrinkflation. It will recover gradually in FY25. (5) International revenue growth was broad based across the regions however, reduced dependence in Bangladesh from 51% in FY22 to ~44% in FY24. (6) Digital first portfolio to grow 2x from current level in FY27 followed by Beardo, Plix and Just herbs (7) Food category gained ~800bps margin led by i) in-house manufacturing; ii) reconfigured supply chain; iii) scale up of Honey and Soya chunks; and iv) softening of input cost. (8) Marico has launched Project Setu movement to increase direct distribution reach to focus on increasing assortments and product range

Quarterly/annual financial summary

20011770										
(INR mn)	Q4FY24	Q4FY23	YoY (%)	Q3FY24	QoQ (%)	FY22	FY23	FY24	FY25E	FY26E
Net Sales	22,780	22,400	1.7	24,220	(5.9)	95,120	97,640	96,530	1,07,840	1,17,909
EBITDA	4,420	3,930	12.5	5,130	(13.8)	16,810	18,100	20,260	22,914	25,895
APAT	3,180	3,020	5.3	3,830	(17.0)	12,250	13,020	14,810	16,586	18,856
EPS (INR)	2.5	2.3	5.3	3.0	(17.0)	9.5	10.1	11.5	12.8	14.6
P/E (x)						54.5	51.2	45.0	40.2	35.4
EV / EBITDA (x)						39.5	36.7	32.5	28.6	25.1
RoCE (%)						55.7	48.2	54.3	63.8	72.5



Consolidated P&L (INR mn)

Year End	FY22	FY23	FY24	FY25E	FY26E
Net Revenues	95,120	97,640	96,530	1,07,840	1,17,909
Growth (%)	18.2	2.6	(1.1)	11.7	9.3
Material Expenses	54,360	53,510	47,480	53,059	57,304
Employee Expense	5,860	6,530	7,430	8,173	8,990
ASP Expense	7,960	8,420	9,520	10,662	11,729
Other expenses	10,130	11,080	11,840	13,032	13,992
EBITDA	16,810	18,100	20,260	22,914	25,895
EBITDA Growth (%)	5.7	7.7	11.9	13.1	13.0
EBITDA Margin (%)	17.7	18.5	21.0	21.2	22.0
Depreciation	1,390	1,550	1,580	1,646	1,796
EBIT	15,420	16,550	18,680	21,268	24,099
Other Income (Including EO Items)	980	1,440	1,420	1,562	1,718
Interest	390	560	730	730	730
PBT	16,010	17,430	19,370	22,100	25,087
Tax	3,460	4,210	4,350	5,304	6,021
RPAT	12,250	13,020	14,810	16,586	18,856
adjustment	-	-	-	-	-
Adjusted PAT	12,250	13,020	14,810	16,586	18,856
APAT Growth (%)	5.7	6.3	13.7	12.0	13.7
Adjusted EPS (Rs)	9.5	10.1	11.5	12.8	14.6
EPS Growth (%)	5.6	6.3	13.7	12.0	13.7

Consolidated Balance Sheet (INR mn)

Year End	FY22	FY23	FY24	FY25E	FY26E
SOURCES OF FUNDS					
Share Capital - Equity	1,290	1,290	1,290	1,290	1,290
Reserves	32,190	36,700	39,228	42,887	47,522
Total Shareholders' Funds	33,480	37,990	40,518	44,177	48,812
Minority Interest	570	1,570	1,780	1,990	2,200
Long Term Debt	-	20	20	20	20
Short Term Debt	3,450	4,730	4,730	4,730	4,730
Total Debt	3,450	4,750	4,750	4,750	4,750
Net Deferred Taxes	(780)	320	320	320	320
Long Term Provisions & Others	1,190	3,810	3,810	3,810	3,810
TOTAL SOURCES OF FUNDS	37,910	48,440	51,178	55,047	59,892
APPLICATION OF FUNDS					
Net Block	14,320	16,690	16,360	15,964	15,418
CWIP	390	670	670	670	670
Other Non-current Assets	6,230	12,500	12,500	12,500	12,500
Total Non-current Assets	20,940	29,860	29,530	29,134	28,588
Inventories	14,120	12,250	12,111	13,530	14,793
Debtors	6,520	10,150	7,934	8,864	9,691
Other Current Assets	8,620	8,180	8,180	8,180	8,180
Cash & Equivalents	5,790	7,560	12,819	16,416	21,214
Total Current Assets	35,050	38,140	41,043	46,989	53,878
Creditors	13,440	14,520	14,355	16,037	17,534
Other Current Liabilities & Provns	4,640	5,040	5,040	5,040	5,040
Total Current Liabilities	18,080	19,560	19,395	21,077	22,574
Net Current Assets	16,970	18,580	21,648	25,912	31,304
TOTAL APPLICATION OF FUNDS	37,910	48,440	51,178	55,047	59,892




Consolidated Cash Flow (INR mn)

Year End	FY22	FY23	FY24	FY25E	FY26E
Reported PBT	16,010	17,430	19,370	22,100	25,087
Non-operating & EO Items	(110)	(580)	-	-	-
Interest Expenses	(200)	70	-	-	-
Depreciation	1,390	1,550	1,580	1,646	1,796
Working Capital Change	(3,420)	(590)	2,190	(667)	(593)
Tax Paid	(3,510)	(3,690)	(4,350)	(5,304)	(6,021)
OPERATING CASH FLOW (a)	10,160	14,190	18,790	17,775	20,269
Capex	(550)	(3,410)	(1,250)	(1,250)	(1,250)
Free Cash Flow (FCF)	9,610	10,780	17,540	16,525	19,019
Investments & Acquisition	690	(2,200)	-	-	-
Non-operating Income	4,110	(3,680)	-	-	-
INVESTING CASH FLOW (b)	4,250	(9,290)	(1,250)	(1,250)	(1,250)
Debt Issuance/(Repaid)	(30)	1,280	-	-	-
Interest Expenses	(1,030)	(940)	-	-	-
FCFE	15,470	4,560	17,540	16,525	19,019
Share Capital Issuance	410	90	-	-	-
Dividend	(11,950)	(5,820)	(12,282)	(12,928)	(14,221)
Others	(280)	(840)	-	-	-
FINANCING CASH FLOW (c)	(12,880)	(6,230)	(12,282)	(12,928)	(14,221)
NET CASH FLOW (a+b+c)	1,530	(1,330)	5,259	3,597	4,798
EO Items, Others	1,069	2,599	1,269	6,528	10,125
Closing Cash & Equivalents	2,599	1,269	6,528	10,125	14,923
Ratios					
Year End	FY22	FY23	FY24	FY25E	FY26E
PROFITABILITY (%)	4.				
GPM	42.9	45.2	50.8	50.8	51.4
EBITDA Margin	17.7	18.5	21.0	21.2	22.0
EBIT Margin	16.2	17.0	19.4	19.7	20.4
APAT Margin	12.9	13.3	15.3	15.4	16.0
RoE	37.2	36.4	37.7	39.2	40.6
RoIC (or Core RoCE)	55.7	48.2	54.3	63.8	72.5
RoCE	33.3	31.8	32.2	33.7	35.3
EFFICIENCY To But (%)	21.6	24.2	22.5	24.0	24.0
Tax Rate (%)	21.6	24.2	22.5	24.0	24.0
Fixed Asset Turnover (x)	8.7	8.2	7.4	7.5	7.6
Inventory (days)	54.2	45.8	45.8	45.8	45.8
Debtors (days)	25.0	37.9	30.0	30.0	30.0
Other Current Assets (days) Payables (days)	33.1	30.6	30.9	27.7	25.3
J , J ,	51.6 17.8	54.3	54.3	54.3	54.3
Other Current Liab & Provns (days)		18.8	19.1	17.1	15.6
Cash Conversion Cycle (days)	42.9 (0.1)	41.2	33.4	32.1	31.2
Net D/E (x)	39.5	(0.1) 29.6	(0.2) 25.6	(0.3) 29.1	(0.3)
Interest Coverage(x)	39.3	29.0	23.6	29.1	33.0
PER SHARE DATA (Rs) EPS	9.5	10.1	11.5	12.8	14.6
CEPS	10.6	11.3	12.7	14.1	16.0
Dividend	9.2	4.5	9.5	10.0	11.0
Book Value	25.9	29.4	31.3	34.2	37.8
VALUATION	23.9	29.4	31.3	34.2	37.0
	54	51	45	40	25
P/E (x) P/BV (x)	19.9	17.6	16.5	15.1	35 13.7
EV/EBITDA (x)	39.5	36.7	32.5	28.6	25.1
EV/Revenues (x)	7.0	6.8	6.8	6.1	5.5
OCF/EV (%)	1.5 1.4	2.1	2.9 2.7	2.7 2.5	3.1
FCF/EV (%)		1.6			2.9
FCFE/Mkt Cap (%)	2.3	0.7	2.6	2.5	2.9
Dividend Yield (%)	1.8	0.9	1.8	1.9	2.1



1 Yr Price Movement



Rating Criteria

BUY: >+15% return potential
ADD: +5% to +15% return potential
REDUCE: -10% to +5% return potential
SELL: > 10% Downside return potential

Marico: 4QFY24 Results Review



Disclosure:

We, Vishal Gutka, CA & Riddhi Shah, MBA authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SEBI conducted the inspection and based on their observations have issued advise/warning. The said observations have been complied with. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does have/does not have any material conflict of interest.

Any holding in stock - No

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

Marico: 4QFY24 Results Review



HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

Please note that HDFC Securities has a proprietary trading desk. This desk maintains an arm's length distance with the Research team and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

HDFC Securities Institutional Equities

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171-7330 www.hdfcsec.com